• Loading stock data…

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Last Updated on March 8, 2022 by GlobeNewsWire

LONDON, March 08, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 – 17, 2022. Iraj Ali, Chief Executive Officer, will present an overview of the company and pipeline on Tuesday, March 15, 2022, at 8:00 am ET / 12:00 pm UK.

A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS(TM) bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.



Achilles Therapeutics
Lee M. Stern, VP, IR & External Communications

LifeSci Advisors
John Mullaly

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virdi, Melissa Gardiner
+44 (0) 203 709 5000

Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Generated by Feedzy
%d bloggers like this: